Bibliography
- Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74
- Lehnart SE, Ackerman MJ, Benson DW Jr, et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation 2007;116:2325-45
- M3(R1): Maintenance of the ICH Guideline on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (1997). Available from: www.ich.org/cache/compo/502-272-1.html#M3
- Preclinical safety evaluation of biotechnology-derived pharmaceuticals. S6. (1997) Available from: www.ich.org/LOB/media/MEDIA503.pdf
- Safety Pharmacology studies for human pharmaceuticals. S7A. (2000). Available from: www.ich.org/LOB/media/MEDIA504.pdf
- The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. (2005) Available from: www.ich.org/LOB/media/MEDIA2192.pdf.
- Critical Path Opportunities Report. Available from: www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf
- Vargas HM, Bass AS, Breidenbach A, et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 2008;58:72-6
- Hanson LA, Bass AS, Gintant G, et al. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 2006;54:116-29
- Sims C, Reisenweber S, Viswanathan PC, et al. Sex, age, and regional differences in L-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with drug-induced long QT type 2. Circ Res 2008;102:e86-e100
- Available from: www.speakblog.org
- Lindgren S, Bass AS, Briscoe R, et al. Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods 2008;58:99-109
- E14: The Clinical Evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (2005). Available from: http://www.ich.org/LOB/media/MEDIA1476.pdf
- Available from: http://www.fda.gov/cder/offices/CSS/presentations.htm: PhRMA-FDA Dialogue Session. February 20, 2008: PhRMA-FDA Dialogue Session Abuse Potential Assessments
- Igarashi T, Nakane S, Kitagawa T. Predictability of clinical adverse reactions of drugs by general pharmacology studies. J Toxicol Sci 1995;20:77-92
- Lawrence CL, Bridgland-Taylor MH Pollard C E, et al. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol 2006;149:845-60